Company / Return on Equity (ROE)
AGIOS PHARMACEUTICALS, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-34.6%
FY2025
5-year range
-81.9% / 124.2%
FY2021-FY2025
Trend
-179.1%
vs FY2024
Sector context
#112 of 190
Health Care
What the data says
AGIOS PHARMACEUTICALS, INC. reports negative total equity of -34.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-34.6% in FY2025 with a 5-year CAGR of +15.7%.
Improved from -43.4% to -34.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +47.3pp
- 5-Year Change
- +15.7pp
- 10-Year Change
- -
Sector benchmark
#112 of 190 in Health CareTop 59% of 190This company -34.6% Sector average -50.4%
▼
+31.4% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 179.1% year-over-year.
- Currently 15.8pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -34.6% | -179.1% |
| FY2024 | 43.7% | +200.7% |
| FY2023 | -43.4% | +47.0% |
| FY2022 | -81.9% | -166.0% |
| FY2021 | 124.2% | +346.8% |
| FY2020 | -50.3% | +21.7% |
| FY2019 | -64.2% | -16.1% |
| FY2018 | -55.4% | +33.9% |
| FY2017 | -83.8% | -51.4% |
| FY2016 | -55.4% | -84.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026